Volara Health announces management crossing, Boadicea integration and recording of ECR ​​2025 research result

Wellington, New ZealandPresent March 3, 2025 / Prnewswire/ Volpara Anformation, a worldwide leading provider of AI-powered breast health solutions and a subsidiary of Lunit, announced three main milestones today:

• Craig HadfieldVolparas Chief Customer and Financial Officer, becomes CEO April 1stsuccessful Teri Thomas When she follows her next career steps.
• The Volpara density is now a validated input for the Boadicea breast cancer.
• In the ECR 2025, a record of 21 independent abstracts with lunit and Volpara solutions was presented.

CEO crossing
Teri Thomaswho had been heading Volpa since 2022, played a key role in the transformation of the company, strengthened its AI platform and supervised his takeover of 2024 by Lunit. After its leadership, the company increased the annual recurring income against over 34 million dollars.

“We deeply appreciate the leadership and influence of Teris,” said Hadfield. “She positioned Volpa for further success and we wish her all the best in her next phase.”

Teri reflected on her term and explained: “It was an honor to lead Volpa and work with an incredible team that drives AI-controlled breast health solutions. I am looking forward to my next chapter, I am a strong supporter of Volpas Mission.”

Hadfield was largely involved in the financial growth of Volara, Saa's crossing and strategic acquisitions. “I feel honored to lead Volpa into his next phase of innovation and effects,” said Craig. “I look forward to working with our teams, partners and customers to promote breast health.”

Vulpara density, which is now integrated into the Boadicea breast crayfish risk model

The Volpara Volumetric breast density evaluation is now a validated input for the newly published version of the BoadICA breast crab risk model. This is a significant milestone, since the Vulpara density is now integrated into two different breast cancer risk models, which are called in the NCCN guidelines-Tyrer-Cuzick and Boadicea, which are sometimes referred to as a canrisk as a web application.

All Vulpara customers can use their Volpara sealing information via Canrisk today. Canrisk is supported by international companies and guidelines for use in use in use Australiathe EU, Great Britain and Canada. Studies have shown that the use of Volpara density in Boadicea to improve model accuracy compared to the use of BI-Rad density categories and the improvement of the skills to evaluate breast cancer for global health service providers worldwide.

A record height 21 Lunit and Vulpara research taxes at ECR 2025

In the ECR 2025, Lunit and Volpas solutions were presented in a record high 21 independent research discounts. This milestone underlines the growing effects of AI-controlled breast health solutions in the global radiology community and reinforces the commitment of Volara and Lunit to promote cancer recognition and patient care through innovation and scientific research.

Via Volpara Health

Volara Health is on the mission to save families from cancer with AI-driven software, which helps the health service providers to better understand the risk of cancer, to lead personalized care decisions and to recommend additional imaging and interventions. Is used in over 3,500 facilities of more than 9,500 technologists worldwide. The Volpara software almost has an effect 18m Patients, support over 3.6 m Annual cancer risk reviews and integrated seamlessly into electronic health records and imaging systems. Volpara helps radiologists to quantify the dense breast fabric with precision, and technologists produce mammograms with optimal positioning, compression and dose. The Volpara software also operates the processes to facilitate compliance and accreditation. Volara, a Lunit company, has its headquarters in Wellington, New Zealandand has an office in Seattle. Volara is the trustworthy partner of leading health facilities worldwide. You can find more information at www.volparahealdh.com.

Source Volpara Health, Inc.